Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine

Thursday, March 12, 2026

2 min read

Canonical Source

USA

Summary Only

What Changed

Moderna announced global regulatory submissions for its investigational mRNA-based seasonal influenza vaccine, mRNA-1010, in key markets including the U.S., EU, Canada, and Australia.

Sigvera Intelligence— Our analysis and strategic assessment of this development.

Source Trust:Discovery

Source Report— Original information from the primary source.

Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for its investigational seasonal influenza vaccine, mRNA-1010.

Read Full Source →

Industry Context

Healthtech & Biotech

Where this signal fits in the broader landscape.

115 industry signalsProduct Launch

View all

Source Verification

Verified from official source

Publisher—

Publication DateMar 12, 2026

Source ClassVerified Canonical

Signal Timeline

First ReportedMar 12, 2026

IndexedMar 12, 2026

PublishedMar 12, 2026

https://www.thetimesherald.com/press-release/story/16604/moderna-announces-global-regulatory-submissions-for-its-investigational-seasonal-influenza-vaccine/

Read Full Source

Get cross-language signal intelligence

Get curated intelligence delivered to your inbox. No spam, unsubscribe anytime.

My Notes

IndustryHealthtech & BiotechRegionUSAEventProduct LaunchSourceCanonical

Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine

See the signals behind market moves.